Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: A randomized, crossover trial

Canadian Journal of Clinical Pharmacology

Volumn 15, Issue 1, 2008, Pages

  Moe, Samantha ^a   Wazny, Lori D ^b   Martin, Janet E ^c  

^a TORONTO EAST GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Alfacalcidol; Calcitriol; Renal dialysis; Secondary hyperparathyroidism; Vitamin D analogues

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM PHOSPHATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL;

EID: 38549164135     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hudson JQ. Secondary hyperparathyroidism in chronic kidney disease: Focus on clinical consequences and vitamin D therapies. Ann Pharmacother 2006;40:1584-93.
2. 3 in early renal failure. Annu Rev Med 1992;43:227-37.
3. Ontario Drug Benefit Formulary, Edition 39, 2005. http://www.health.gov. on.ca/english/providers/program/drugs/edition_39.html (March 9, 2007).
4. Herrmann P, Ritz E, Schmidt-Gayk H, et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 1994;67:48-53.
5. Moe SM, Krauss MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998;13:1234-41.
6. Diagnostic Products Corporation. Immulite 2000 - Intact PTH Package Insert. Oct. 2001.
7. 3 using non-ene-capped C18 silica: performance and validation. In: Norman AW, Schaefer K, Grigoleit H-G, vHerrath D, eds. Vitamin D: Molecular, Cellular and Clinical Endocrinology. Berlin: W de Gruyter, 1988:710-719.
8. 3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997;17:505-10.
9. 3 on the suppression of plasma PTH levels in uremic patients, evaluated by the "whole" and "intact" PTH assays. Nephron Clin Pract 2005;99:c128-37.
10. Arenas MD, Muray S, Amoedo ML, Egea JJ, Millan I, Gil MT. A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis. Nefrologia 2006;26:226-33.
11. 3. Q J Med 1979;190:289-322.
12. Salusky IB, Goodman WG, Horst R, et al. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 1990;16:126-32.
13. Joffe P, Cintin C, Ladefoged SD, Rasmussen SN. Pharmacokinetics of 1alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol 1994;41:364-9.
14. 3. J Biol Chem 1983;258:2100-7.
15. 3 in chronic renal failure. Nephron 1991;58:144-9.